不同劑量右美托咪定復(fù)合乳化依托咪酯在無痛腸鏡中的應(yīng)用研究
本文選題:右美托咪定 + 乳化依托咪酯; 參考:《浙江大學(xué)》2014年碩士論文
【摘要】:研究背景: 現(xiàn)代醫(yī)學(xué)的發(fā)展,生活條件的改善,健康意識的加強,患者對腸鏡檢查的要求越來越高。麻醉狀態(tài)下實施電子腸鏡檢查診療,不僅能消除患者的焦慮、緊張、恐懼情緒,提高了電子腸鏡檢查的準(zhǔn)確率,同時能提高患者的耐受性、改善患者的自覺癥狀及降低腸鏡操作難度,避免了以往因恐懼而拒絕檢查或者檢查時不配合操作而延長操作時間、甚至終止操作等情況。無痛腸鏡要求麻醉誘導(dǎo)安全舒適、平穩(wěn),內(nèi)鏡操作者滿意,麻醉后蘇醒迅速而安全,患者無不適感。呼吸抑制是無痛腸鏡的最常見并發(fā)癥,嚴(yán)重者可致患者死亡。 當(dāng)前,丙泊酚是無痛腸鏡最常使用的麻醉藥物,但可引起一過性的呼吸抑制,與阿片類藥物合用可加重呼吸抑制和蘇醒延遲,并導(dǎo)致血流動力學(xué)不穩(wěn)定,以及麻醉蘇醒時的躁動、譫妄等。依托咪酯是臨床較常用的靜脈麻醉藥,具有起效快,呼吸循環(huán)抑制輕等特點,也常用于無痛腸鏡的檢查,但誘導(dǎo)時易發(fā)生注射痛、肌陣攣和惡心嘔吐等并發(fā)癥。乳化依托咪酯的使用減少了依托咪酯的注射痛和惡心嘔吐的發(fā)生率,但肌陣攣的發(fā)生率仍較高。雖有很多研究報道單次推注和持續(xù)輸注乳化依托咪酯是安全可行的,并通過復(fù)合使用其他藥物來減少乳化依托咪酯的不良反應(yīng),如復(fù)合咪達唑侖來減少乳化依托咪酯所致的肌陣攣,但總體效果都不理想。右美托咪定是一種新型的α2腎上腺素受體激動劑,具有鎮(zhèn)靜、鎮(zhèn)痛和抗交感神經(jīng)作用,能夠減少鎮(zhèn)靜鎮(zhèn)痛藥物的使用量,降低心腦血管不良事件的發(fā)生率,且無呼吸抑制,具有獨特的生理睡眠狀態(tài)。有研究結(jié)果顯示,右美托咪定能減少依托咪酯所致的肌陣攣發(fā)生,但是不同劑量右美托咪定復(fù)合乳化依托咪酯在無痛腸鏡檢查中的應(yīng)用研究未有報道。 研究目的: 觀察單次泵注不同劑量右美托咪定對乳化依托咪酯在無痛腸鏡中應(yīng)用的有效性以及不良反應(yīng)的影響。 研究方法: 經(jīng)倫理委員會批準(zhǔn),并獲得患者或家屬知情同意后,采用隨機數(shù)字表法將80例擬行無痛腸鏡的患者隨機分入4組,在給予乳化依托咪酯麻醉前分別泵注0.9%氯化鈉溶液(對照組)、右美托咪定0.6μg/kg (0.6μg/kg組)、右美托咪定1.0μg/kg(1.0μg/kg組)和右美托咪定1.4μg/kg (1.4μg/kg組),觀察并記錄4組乳化依托咪酯的劑量,患者血流動力學(xué)指標(biāo)、蘇醒時間、離室時間,肌陣攣、術(shù)后不良反應(yīng)情況,以及術(shù)中操作醫(yī)師和患者的滿意度。 研究結(jié)果: 右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組、右美托咪定1.4μg/kg組的乳化依托咪酯誘導(dǎo)用量和總用量均顯著低于對照組(P值均0.05),4組間的腸鏡檢查時間和患者清醒時間的差異均無統(tǒng)計學(xué)意義(P值均0.05),右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組患者的離室時間均顯著短于對照組和右美托咪定1.4μg/kg組(P值均0.05)。4組間T0時間點的MAP、HR、SpO2的差異均無統(tǒng)計學(xué)意義(P值均0.05),對照組、右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組T1-T5時間點的MAP均顯著低于右美托咪定1.4μg/kg組同時間點(P值均0.05),右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組T1、T2、T4、T5時間點的HR均顯著低于對照組同時間點(P值均0.05),對照組、右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組T1、T2時間點的Sp02均顯著高于右美托咪定1.4μg/kg組(P值均0.05)。右美托咪定0.6μg/kg組、右美托咪定1.0μg/kg組、右美托咪定1.4μg/kg組的肌陣攣、惡心嘔吐發(fā)生率均顯著低于對照組(P值均0.05),4組間注射痛和夢境發(fā)生率的差異均無統(tǒng)計學(xué)意義(P值均0.05)。右美托咪定0.6μg/kg組、1.0μg/kg組、1.4μg/kg組操作醫(yī)師的滿意率均顯著高于對照組(P值均0.05),右美托咪定0.6μg/kg組、1.0μg/kg組患者滿意率均顯著高于對照組和右美托咪定1.4μg/kg組(P值均0.05)。結(jié)論: 右美托咪定0.61μg/kg組和1.0μg/kg組單次注射復(fù)合乳化依托咪酯能夠安全應(yīng)用于無痛腸鏡中,并且能夠降低相應(yīng)肌陣攣、惡心嘔吐等不良反應(yīng)的發(fā)生率。
[Abstract]:Research background:
The development of modern medicine, the improvement of living conditions, the strengthening of health awareness, and the increasing demand for the patient's examination of enteroscopy. The implementation of the electronic colonoscopy under anesthesia can not only eliminate the anxiety, tension, and fear of the patients, improve the accuracy of the electronic colonoscopy, but also improve the patient's tolerance and improve the patient's self - tolerance. The symptoms and the difficulty of reducing the operation of the enteroscopy, avoid the prior period of refusing to check or check or check the operation time, and even terminate the operation. The painless enteroscopy requires anesthesia induction safety, comfort, smooth, endoscopic operator satisfaction, rapid and safe recovery after anesthesia, and the patient's feeling of no pain. Respiratory depression is painless. The most common complication of colonoscopy is severe death.
At present, propofol is the most commonly used anesthetic in painless colonoscopy, but it can cause an excessive respiratory inhibition. Combined with opiates can aggravate respiratory depression and wake up delay, lead to hemodynamic instability, as well as restlessness and delirium in the wake of anaesthesia. The use of respiratory and circulation inhibition is also often used in the examination of painless colonoscopy, but it is prone to complications such as injection pain, myoclonus and nausea and vomiting. The use of etomidate emulsified reduces the incidence of injection pain and nausea and vomiting of etomidate, but the incidence of myoclonus is still high. Although many studies have reported single push and holding. Continuous infusion of etomidate is a safe and feasible way to reduce the adverse effects of emulsified etomidate by compound use of other drugs, such as midazolam compound to reduce the myoclonus caused by the emulsified etomidate, but the overall effect is not ideal. Dexmedetomidine is a new type of alpha 2 adrenergic receptor agonist, with sedative, town Pain and resistance to sympathetic nerve can reduce the use of sedative and analgesic drugs, reduce the incidence of adverse events in the heart and brain vessels, and have no respiratory inhibition, and has a unique physiological sleep state. The application of ometamidate in painless colonoscopy has not been reported.
The purpose of the study is:
Objective To observe the efficacy and adverse reactions of single dose infusion of dexmedetomidine in the application of emulsified etomidate in painless enteroscopy.
Research methods:
After the approval of the ethics committee and the informed consent of the patients or family members, 80 patients with painless enteroscopy were randomly divided into 4 groups by random numerals, 0.9% Sodium Chloride Solution (control group), right metomomidine 0.6 mu g/ kg (0.6 mu g/kg group), and right metomomidine 1 g/kg (1 mu g/kg group) before the anesthesia was given to the emulsified etomidate. The dosage of 4 groups of emulsified etomidate, the hemodynamic index, the time of waking up, the room time, the myoclonus, the postoperative adverse reaction, and the satisfaction of the operation doctors and patients were observed and recorded in the dosage of 4 groups of emulsified etomidate (1.4 Mu group) and right metodetomidine (1.4 u g/kg group).
The results of the study:
Dexmedetomidine group 0.6 g/kg, dexmedetomidine group 1 g/kg, right metomomomidine 1.4 mu g/kg group of emulsified etomidate induced dosage and total dosage were significantly lower than the control group (P values are 0.05), the 4 groups of enteroscopy time and patient waking time difference were not statistically significant (P value of 0.05), right metomomidin group 0.6 g/kg, right metomi The time of isolation of the 1 g/kg group was significantly shorter than that of the control group and the right metomomomidine group (0.05) of the 1.4 g/kg group (P value 0.05).4 group MAP, HR, SpO2 were not statistically significant (P value 0.05), the control group, right metomomidine 0.6 micron g/kg group, right metomomidin 1 mu g/kg group T1-T5 time points were significantly lower than right metomidine 1.4 The same time point (P value was 0.05), dexmedetomidine group 0.6 g/kg, T1, T2, T4, T5 time point in right metomomomididine group of T1, T2, T4, T5 time point was significantly lower than the control group at the same time point (P value 0.05), the control group, right metomomidine 0.6 Mu g/kg group, right metomomidin 1 mu g/kg group. 0.05). Right metodetomidine group 0.6 g/kg, right metomomomidine 1 u g/kg group, right metomomomidin group of myoclonus, the incidence of nausea and vomiting was significantly lower than the control group (P value is 0.05), the difference between the 4 groups of injection pain and dream incidence was not statistically significant (P value 0.05). Right metodetomidine group 0.6 mu, 1 u g/kg group, 1.4 u g/kg group exercise. The satisfaction rate of the doctors was significantly higher than that of the control group (P value 0.05), right metomomidine 0.6 g/kg group, and 1 mu g/kg group were significantly higher than the control group and right metomomidine group 1.4 g/kg group (P value 0.05).
A single injection of etomidate of right metodetomidine in 0.61 and 1 g/kg groups can be safely used in painless colonoscopy and can reduce the incidence of adverse reactions such as the corresponding myoclonus, nausea and vomiting.
【學(xué)位授予單位】:浙江大學(xué)
【學(xué)位級別】:碩士
【學(xué)位授予年份】:2014
【分類號】:R614.24
【相似文獻】
相關(guān)期刊論文 前10條
1 王晨笛,謝彥梅;依托咪酯用于無痛人流產(chǎn)150例的臨床分析[J];中國醫(yī)師雜志;2003年S1期
2 王天德;依托咪酯用于老年及危重病人全麻誘導(dǎo)的臨床觀察[J];山西醫(yī)藥雜志;2004年03期
3 張軍,莊心良,趙新峰,李士通,王瑩恬;依托咪酯對大鼠腦皮層突觸體內(nèi)鈣動力學(xué)的影響[J];中華麻醉學(xué)雜志;2005年09期
4 ;依托咪酯可減少術(shù)中低血壓發(fā)生[J];河南醫(yī)學(xué)研究;2006年02期
5 李秀華;高爾;張巖;;依托咪酯脂肪乳劑的實驗學(xué)研究及臨床應(yīng)用[J];醫(yī)學(xué)綜述;2006年24期
6 袁文峰;;依托咪酯與咪唑安定在胃境檢查中的臨床觀察[J];當(dāng)代醫(yī)學(xué)(學(xué)術(shù)版);2008年02期
7 劉健慧;郁慶;張曉慶;;兩種劑型依托咪酯在心臟手術(shù)全麻誘導(dǎo)中的應(yīng)用比較[J];同濟大學(xué)學(xué)報(醫(yī)學(xué)版);2008年02期
8 闞永星;;依托咪酯在無痛人工流產(chǎn)術(shù)中的應(yīng)用[J];臨床麻醉學(xué)雜志;2009年06期
9 韋云芳;劉先波;;靜脈注射依托咪酯過敏反應(yīng)1例[J];武警醫(yī)學(xué);2009年06期
10 張小光;張欣光;;依托咪酯用于老年手術(shù)麻醉的臨床觀察[J];河南外科學(xué)雜志;2010年06期
相關(guān)會議論文 前10條
1 李優(yōu)春;王志萍;;依托咪酯的即時輸注半衰期[A];全國第一次麻醉藥理學(xué)術(shù)會議暨中國藥理學(xué)會麻醉藥理專業(yè)委員會籌備會論文匯編[C];2010年
2 胡紅專;秦榜勇;曹保鋒;朱昭瓊;張紅;;依托咪酯持續(xù)輸注對犬腎上腺功能影響的實驗研究[A];第一屆全國麻醉藥理專業(yè)委員會第二次學(xué)術(shù)會議論文集[C];2011年
3 繆秀華;宋德富;高玉杰;郭傳東;沈建明;黃林英;;咪達唑侖和依托咪酯麻醉誘導(dǎo)的相互作用和優(yōu)化配伍方案[A];2009年浙江省麻醉學(xué)學(xué)術(shù)會議論文匯編[C];2009年
4 漆勇;郭建榮;;依托咪酯脂肪乳劑在老年手術(shù)患者全麻誘導(dǎo)中的應(yīng)用[A];2009年浙江省麻醉學(xué)學(xué)術(shù)會議論文匯編[C];2009年
5 陳娟;孫鑫;傅婕;顧曉靈;王丹;;依托咪酯對小鼠缺氧耐受力的影響[A];第一屆全國麻醉藥理專業(yè)委員會第二次學(xué)術(shù)會議論文集[C];2011年
6 朱利斌;;依托咪酯用于老年手術(shù)患者全麻誘導(dǎo)的臨床觀察[A];浙江省第二十屆基層衛(wèi)生改革與發(fā)展學(xué)術(shù)會議大會論文集[C];2012年
7 王榮金;范榮林;;先注原則對依托咪酯不良反應(yīng)控制效果的臨床觀察[A];2006年浙江省麻醉學(xué)學(xué)術(shù)年會論文匯編[C];2006年
8 吳江;黃德櫻;;預(yù)注小劑量依托咪酯減低嬰幼兒依托咪酯氣管插管全身麻醉快誘導(dǎo)后肌緊張和肌陣攣[A];2014年全國小兒麻醉學(xué)術(shù)年會暨浙江省麻醉學(xué)學(xué)術(shù)年會論文集[C];2014年
9 曹保鋒;秦榜勇;李文宇;;依托咪酯持續(xù)輸注對失血性休克犬腎上腺皮質(zhì)功能影響的實驗研究[A];全國第三次麻醉藥理學(xué)術(shù)會議論文集[C];2012年
10 李恒;馮舒韻;陳華艷;楊承祥;;新型阿片類藥物減少依托咪酯致肌震顫的效果觀察[A];全國第一次麻醉藥理學(xué)術(shù)會議暨中國藥理學(xué)會麻醉藥理專業(yè)委員會籌備會論文匯編[C];2010年
相關(guān)博士學(xué)位論文 前3條
1 張軍;依托咪酯對大鼠大腦皮層突觸體內(nèi)鈣動力學(xué)及神經(jīng)遞質(zhì)釋放的影響[D];復(fù)旦大學(xué);2004年
2 蔣暉;依托咪酯對大鼠海馬CA1區(qū)突觸傳遞和可塑性的影響[D];新疆醫(yī)科大學(xué);2006年
3 張貞雄;依托咪酯在大鼠脊髓背角神經(jīng)元上的直接電生理作用及其對GABA_A受體和甘氨酸受體調(diào)控的研究[D];中國協(xié)和醫(yī)科大學(xué);2002年
相關(guān)碩士學(xué)位論文 前10條
1 盧娜;依托咪酯對點燃模型的作用及機制研究[D];青島大學(xué);2009年
2 張日鳳;依托咪酯對腎上腺皮質(zhì)功能影響的研究[D];廣西醫(yī)科大學(xué);2006年
3 孫學(xué)軍;依托咪酯對人外周血單個核細(xì)胞凋亡及細(xì)胞毒效應(yīng)的影響[D];大連醫(yī)科大學(xué);2007年
4 馮超男;持續(xù)靜脈泵注依托咪酯用于腹腔鏡膽囊切除術(shù)患者的臨床研究[D];蘇州大學(xué);2014年
5 崔明珠;靶控輸注依托咪酯在老年病人麻醉中的研究[D];鄭州大學(xué);2009年
6 曹保鋒;依托咪酯持續(xù)輸注對失血性休克犬腎上腺皮質(zhì)功能影響的實驗研究[D];遵義醫(yī)學(xué)院;2012年
7 王泓源;不同濃度依托咪酯誘導(dǎo)人肝癌HepG2細(xì)胞體外凋亡的研究[D];山西醫(yī)科大學(xué);2014年
8 陳武;依托咪酯持續(xù)輸注對術(shù)后認(rèn)知功能的影響[D];遵義醫(yī)學(xué)院;2014年
9 王玲玲;依托咪酯全憑靜脈麻醉對老年骨科患者術(shù)后譫妄的影響[D];吉林大學(xué);2013年
10 戰(zhàn)海燕;依托咪酯全憑靜脈麻醉對老年骨科患者術(shù)中應(yīng)激反應(yīng)和早期術(shù)后認(rèn)知功能障礙發(fā)生率的影響[D];吉林大學(xué);2014年
,本文編號:2069724
本文鏈接:http://sikaile.net/yixuelunwen/mazuiyixuelunwen/2069724.html